CCL2 and neoplasm: Therefore, the combination therapy with TTFields and anti-PD-1 activates STAT1 and IRF1 through ICD in tumor tissue, enhancing the CCL2/8-CCR2 axis and CXCL9/10-CXCR3 axis, which recruits CD8+ T and CD4+ T cells to infiltrate and kill tumor cells.